https://doi.org/10.55788/257d2b41
“As we know, patients with PsA are at increased risk of developing cardiovascular disease, and these PsA patients also have increased traditional risk factors, such as diabetes, obesity, or smoking. But this does not fully explain the elevated cardiovascular risk in the PsA population,” Dr Nienke Kleinrensink (UMC Utrecht, the Netherlands) explained the motivation for their research [1]. The retrospective Dutch study investigated whether inflammation in patients with PsA may also be present within the vascular system. As means of vascular inflammation determination, 18F-FDG PET/CTs with TBR of the aorta were used, a method that has been determined to be a reliable and reproducible measure [2,3].
The analysis included 75 PsA patients with active peripheral arthritis from an ongoing clinical trial (EudraCT 2017- 003900-28) with a median age of 53, a median swollen joint count of 3, and a mean affected body surface area of 1 [1]. This cohort was compared with a control group of 40 melanoma patients without distant metastases, who neither had auto-immune disease nor were treated with checkpoint inhibitors. “We found no difference in age, blood pressure, or gender, but patients with PsA had a slightly higher BMI than the control group,” Dr Kleinrensink commented on the baseline characteristics. Both groups comprised about 57% of men, and around 15% had prior cardiovascular disease.
The results showed significantly increased vascular inflammation in PsA versus controls, not only when evaluating the entire aorta (P≤0.001) but also in its 5 different sub-segments. These findings remained significant after a multivariate analysis that corrected for traditional cardiovascular risk factors, including age, sex, BMI, and mean arterial pressure.
“We also measured clinical measures of disease activity, such as tender joints count, swollen joints count, enthesitis index, BSA affected psoriasis, and inflammation parameters, but these were not associated with vascular inflammation assessed on PET/CT,” Dr Kleinrensink informed.
In her summary, she said that the study confirms that there is indeed systemic inflammation going on in PsA. “It would be interesting for future studies to assess the effect of PsA treatment on vascular inflammation,” Dr Kleinrensik concluded.
- Kleinrensink NJ, et Increased vascular inflammation on PET-CT in psoriatic arthritis patients in comparison with healthy controls. OP0026, EULAR 2023, 31 May–3 June, Milan, Italy.
- Rudd JHF, et J Am Coll Cardiol. 2007;50:892-6.
- Bucerius J, et Eur J Nucl Med Mol Imaging. 2016;43:780-92.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Obesity in PsA is increasingly affecting male patients Next Article
AxSpA: Adalimumab biosimilar equally effective as IL-17 inhibitor in hindering radiographic progression »
« Obesity in PsA is increasingly affecting male patients Next Article
AxSpA: Adalimumab biosimilar equally effective as IL-17 inhibitor in hindering radiographic progression »
Table of Contents: EULAR 2023
Featured articles
Late-breaking Oral Abstracts
Selective JAK1/TYK 2 inhibitor effective in patients with difficult-to-treat RA
Novel 2-drug combo improves treatment possibilities for patients with refractory gout
Dazodalibep improves dryness, fatigue, and pain in patients with Sjögren’s syndrome with a high symptom burden
COVID-19: Young adults with auto-immune diseases have different risks than their healthy counterparts
RA in 2023
Poly-refractory RA: not common, but still present
AI almost as successful as experts in predicting early RA
Worse self-management in patients with inflammatory arthritis in the presence of comorbid anxiety or depression
Disease activity-guided dose reduction may be a long-term option for stable RA
Cardiovascular safety of JAK inhibitors: reassuring results from a real-world study
Spondylarthropathies: New Developments
AxSpA: Adalimumab biosimilar equally effective as IL-17 inhibitor in hindering radiographic progression
Vascular inflammation may be characteristic of PsA
Obesity in PsA is increasingly affecting male patients
PsA patients: highest risk of developing NAFLD
What is Hot in Osteoarthritis
Lorecivivint shows long-term benefits for severe knee OA
Methotrexate lowers pain in inflammatory hand OA
Systemic Sclerosis: State of the Art
Targeted DMARDs advantageous in SSc patients with pre-capillary pulmonary hypertension
Osteoporosis: New Data
Drugs for osteoporosis: time to reach fracture risk reduction varies
Romosozumab: the new option for glucocorticoid-induced osteoporosis with high fracture risk?
Best of the Posters
Therapy with biological DMARDs shows no correlation with fracture risk in RA
Basic Science
In vitro and in vivo studies confirm the role of regulatory volume decrease
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com